RIGL icon

Rigel Pharmaceuticals

37.30 USD
-0.66
1.74%
At close Updated Sep 15, 4:00 PM EDT
Pre-market
After hours
37.30
0.00
0%
1 day
-1.74%
5 days
-8.24%
1 month
-5.59%
3 months
82.57%
6 months
77.37%
Year to date
115.36%
1 year
171.27%
5 years
51.01%
10 years
12.01%
 

About: Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Employees: 164

0
Funds holding %
of 7,463 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

48,650% more call options, than puts

Call options by funds: $975K | Put options by funds: $2K

25% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 36

12% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 17

2% more funds holding

Funds holding: 123 [Q1] → 125 (+2) [Q2]

4% more capital invested

Capital invested by funds: $250M [Q1] → $260M (+$10.1M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

0.14% less ownership

Funds ownership: 77.84% [Q1] → 77.7% (-0.14%) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$32
14% downside
Avg. target
$32
14% downside
High target
$32
14% downside

1 analyst rating

positive
0%
neutral
100%
negative
0%
Cantor Fitzgerald
Kristen Kluska
$32
Neutral
Maintained
6 Aug 2025

Financial journalist opinion

Based on 4 articles about RIGL published over the past 30 days

Positive
Zacks Investment Research
4 days ago
Can Tavalisse Drive Rigel's Growth Through the Rest of 2025?
RIGL's top line keeps growing on strong sales momentum for lead product, Tavalisse, while other products support growth.
Can Tavalisse Drive Rigel's Growth Through the Rest of 2025?
Positive
Zacks Investment Research
6 days ago
What Makes Rigel Pharmaceuticals (RIGL) a Strong Momentum Stock: Buy Now?
Does Rigel Pharmaceuticals (RIGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Rigel Pharmaceuticals (RIGL) a Strong Momentum Stock: Buy Now?
Neutral
PRNewsWire
20 days ago
Rigel to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Aug. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September: Citi's 2025 Biopharma Back to School Conference in Boston, MA Rigel will participate in one-on-one meetings on Tuesday, September 2.
Rigel to Participate in Upcoming September Investor Conferences
Positive
Zacks Investment Research
21 days ago
Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out?
Positive
Schwab Network
1 month ago
Overlooked Stock: RIGL Nearly Doubles Stock in August
Rigel Pharmaceuticals (RIGL) is up 88% in August and more than tripled its stock price over the last year. The staggering upside rally began with a massive earnings beat and raised guidance.
Overlooked Stock: RIGL Nearly Doubles Stock in August
Positive
Schwab Network
1 month ago
The Big 3: OPEN, RIGL, JOBY
@Stockstotrade's Tim Bohen talks about Opendoor's (OPEN) "fundamental case" for real estate, even after shares exploded to the upside in an ongoing meme stock craze. He sees something similar in Rigel Pharmaceuticals (RIGL), noting the stock nearly doubling just in August.
The Big 3: OPEN, RIGL, JOBY
Positive
Seeking Alpha
1 month ago
Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout
Rigel's Q2 results were outstanding, with revenue nearly doubling and net income surging, driven by strong commercial momentum for TAVALISSE, GAVRETO, and REZLIDHIA. Management raised 2025 guidance, expecting positive net income and robust sales growth, signaling Rigel's transition to a self-sustaining, growth-focused biotech. Pipeline progress, especially with R289 and REZLIDHIA label expansion, offers long-term catalysts, but investors must weigh risks from nonrecurring revenue and clinical execution.
Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout
Positive
Zacks Investment Research
1 month ago
Earnings Estimates Moving Higher for Rigel (RIGL): Time to Buy?
Rigel Pharmaceuticals (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Earnings Estimates Moving Higher for Rigel (RIGL): Time to Buy?
Positive
Zacks Investment Research
1 month ago
Best Momentum Stock to Buy for August 8th
RIGL, APG and CLSK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 8, 2025.
Best Momentum Stock to Buy for August 8th
Neutral
Zacks Investment Research
1 month ago
5 Best Stocks With Relative Price Strength to Buy Right Now
LendingTree, RIGL, and others are standing out with strong relative price strength amid market volatility.
5 Best Stocks With Relative Price Strength to Buy Right Now
Charts implemented using Lightweight Charts™